# Journey Medical Corporation (DERM) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/DERM
## Company Profile
- Ticker: DERM
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 6.4 USD
- Market cap: 165757972.94 USD
- Last updated: 2026-08-05
## Business Overview
### Prescription Dermatology Company
Journey Medical develops, acquires, and commercializes FDA-approved prescription products for dermatologic conditions through a specialist sales organization.
### Emrosi
Emrosi is the company’s newer treatment for inflammatory lesions of rosacea and is central to its current commercial expansion.
### Established Portfolio
Journey also markets a broader group of branded dermatology products, allowing its sales infrastructure to support multiple prescriptions and disease categories.
### Efficient Commercial Model
The company emphasizes targeted product acquisition and focused physician promotion rather than maintaining a broad internal drug-discovery platform.
## Why The Stock Is Moving

The latest monitored headline was “Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026”. DERM was little changed in the corresponding trading session, closing at $6.40 on Aug 5, 2026.

## Future Catalysts

- The main thing to watch at Journey Medical Corporation is its latest development priorities. The update that sharpened the story was FDA Approval of Emrosi™ (Minocycline Hydrochloride) Extended-Release Capsules, 40mg for Treatment of Papulopustular Rosacea. That is the part of the story investors will probably keep circling back to.

## Recent News
- 2026-08-05 12:30 EST — [Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026](https://biopharmsignal.com/news/DERM/journey-medical-corporation-to-announce-second-quarter-2026-financial-results-on-2458bb4f) — Source: Journey Medical Corporation
- 2026-05-19 20:45 EST — [Journey Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference](https://biopharmsignal.com/news/DERM/journey-medical-corporation-to-participate-in-a-g-p-s-annual-virtual-healthcare-conference) — Source: Journey Medical Corporation
- 2026-05-13 20:01 EST — [Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights](https://biopharmsignal.com/news/DERM/journey-medical-corporation-reports-first-quarter-2026-financial-results-and-rec-ed65bf9d) — Source: Journey Medical Corporation
- 2026-05-06 20:01 EST — [Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026](https://biopharmsignal.com/news/DERM/journey-medical-corporation-to-announce-first-quarter-2026-financial-results-on--4fe55408) — Source: Journey Medical Corporation
- 2026-04-21 12:30 EST — [Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™](https://biopharmsignal.com/news/DERM/journey-medical-corporation-secures-contract-with-third-major-gpo-for-emrositm) — Source: Journey Medical Corporation